Drug Delivery Business7 天
Why Dexcom is making a push to bring CGM to more people with type 2 diabetes
Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.
Zacks.com on MSN1 天
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...
Medscape4 天
Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
Drug Delivery Business9 天
Dexcom CGM now connects with Novo Nordisk smart insulin pens, 15-day CGM shows promise
Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...
Modern Healthcare3 天
FDA warns Dexcom over continuous glucose monitor testing
The Food and Drug Administration on Tuesday released a warning letter that it sent to medical device company Dexcom on March 4 citing quality issues at the facilities responsible for testing its ...
DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter
Key Takeaways DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.The maker of glucose monitoring devices said investigations of its San ...
来自MSN1 个月
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
DexCom, Inc. DXCM reported fourth-quarter 2024 ... The broader S&P 500 Index has moved up 10% in the same period. Image Source: Zacks Investment Research Sensor and other revenues (96% of total ...